CareRx Crecimiento futuro
Future controles de criterios 0/6
Se prevé que los beneficios de CareRx disminuyan a un ritmo anual de 54.6%, mientras que sus ingresos anuales crecerán a un ritmo de 4% por año. Se espera que el BPA disminuya en un 12.5% al año.
Información clave
-54.6%
Tasa de crecimiento de los beneficios
-12.51%
Tasa de crecimiento del BPA
| Crecimiento de los beneficios de Consumer Retailing | 5.7% |
| Tasa de crecimiento de los ingresos | 4.0% |
| Rentabilidad financiera futura | n/a |
| Cobertura de analistas | Good |
| Última actualización | 11 May 2026 |
Actualizaciones recientes sobre el crecimiento futuro
Recent updates
Actualización de narrativa • May 04
CRRX: Completed Buyback And Stable Assumptions Will Support Long Term Upside
Analysts have nudged their CareRx price target slightly higher to CA$4.50, reflecting modest adjustments to the discount rate, revenue growth assumptions, profit margin outlook and future P/E expectations. What's in the News CareRx completed a share repurchase of 246,069 shares between October 1, 2025 and March 4, 2026, equal to 0.39% of its shares, for a total of CA$0.49 million (Key Developments).Actualización de narrativa • Apr 19
CRRX: Share Repurchase And Steady Assumptions Will Support Long Term Upside
Analysts have made slight adjustments to their CareRx price targets, reflecting updated views on discount rates, revenue growth, profit margins, and future P/E assumptions. Their fair value estimate remains steady at CA$4.50.Actualización de narrativa • Apr 05
CRRX: Share Repurchase And Margin Outlook Will Support Long Term Upside
Analysts have modestly revised their CareRx price target to CA$4.50, reflecting updated assumptions for discount rate, revenue growth, profit margins and future P/E, which keep the fair value estimate steady at CA$4.50. What's in the News CareRx completed a share repurchase of 246,069 shares, representing 0.39% of its shares, for a total of CA$0.49 million under the buyback announced on September 15, 2025 (Key Developments).
Actualización de narrativa • Mar 22
CRRX: Share Repurchases And Higher Assumed P/E Will Support Future Upside
Analysts have adjusted their CA$ fair value estimate for CareRx from about CA$5.08 to roughly CA$5.38, reflecting updated views on revenue growth, profit margins, and future P/E assumptions. What's in the News CareRx completed a share repurchase program, buying back 246,069 shares between October 1, 2025 and March 4, 2026, equal to 0.39% of its shares, for a total of CA$0.49 million (Key Developments).Actualización de narrativa • Mar 07
CRRX: Improved Profit Outlook And Lower P/E Will Support Future Upside
Analysts have adjusted their CareRx price target slightly higher to CA$5.08 from CA$4.92, reflecting updated views on fair value, discount rate, revenue growth, profit margin, and future P/E assumptions. Valuation Changes Fair Value: CA$5.08, up slightly from CA$4.92.Actualización de narrativa • Feb 21
CRRX: Lower Future P/E Will Support Stronger Shareholder Returns
Analysts have trimmed their target price on CareRx to CA$4.92. They link this move to slightly higher discount rate assumptions and a modestly lower revenue growth outlook, partially balanced by a small improvement in expected profit margins and a lower future P/E estimate.Actualización de narrativa • Feb 06
CRRX: Refined Earnings Assumptions Will Support Stronger Long Term Upside Potential
Analysts have slightly adjusted their price target on CareRx, citing updated assumptions around revenue growth, profit margins, discount rate and future P/E that fine tune rather than overhaul their previous fair value view. Valuation Changes Fair Value: Unchanged at 4.5x, indicating no shift in the overall valuation anchor used in the model.Actualización de narrativa • Jan 23
CRRX: Future Earnings Power Will Support Refined Fair Value Upside
Analysts have slightly adjusted their price target on CareRx, reflecting modest tweaks to the discount rate, revenue growth, profit margin and future P/E assumptions. Together these changes point to a more refined view of the company’s fair value around $4.50.Actualización de narrativa • Jan 09
CRRX: Future Earnings Power Will Drive Repriced Market Expectation
The analyst price target for CareRx has shifted from US$2.25 to US$4.50, with analysts attributing this change to updated assumptions about revenue growth, profitability, and future P/E. What's in the News Between September 15, 2025 and September 30, 2025, CareRx reported no share repurchases under its existing buyback program, with 0 shares repurchased for CAD 0 million in that period (Key Developments).Actualización de narrativa • Dec 24
CRRX: Higher Future Earnings Multiple Will Drive Stronger Shareholder Returns
Analysts have nudged their price target for CareRx slightly higher, raising it by about $0.06 per share. This reflects modestly stronger expectations for revenue growth and valuation multiples, despite a more cautious view on profit margins.Actualización de narrativa • Dec 10
CRRX: Upcoming Share Buybacks Will Support Stronger Future Shareholder Returns
Narrative Update on CareRx Analysts have modestly increased their price target on CareRx to reflect a slightly higher valuation multiple and stable expectations for revenue growth and profit margins. This translates into a small upward adjustment in projected equity value by a few cents per share.Actualización de narrativa • Nov 26
CRRX: Share Repurchase Program Will Drive Stronger Performance Ahead
Analysts have raised their price target for CareRx, increasing the fair value estimate from $4.00 to $4.86. This change reflects improved revenue growth expectations and a more favorable profit margin outlook.Artículo de análisis • Sep 11
Is CareRx (TSE:CRRX) A Risky Investment?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
Nueva narrativa • Apr 07
North Burnaby Fulfillment Center And European Automation Will Improve Operations
Debt restructuring and cost-saving measures likely increase net margins and improve earnings by reducing interest expenses and operational costs.Artículo de análisis • Feb 11
Market Participants Recognise CareRx Corporation's (TSE:CRRX) Revenues
It's not a stretch to say that CareRx Corporation's ( TSE:CRRX ) price-to-sales (or "P/S") ratio of 0.4x right now...Artículo de análisis • Oct 03
CareRx (TSE:CRRX) Seems To Use Debt Quite Sensibly
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Artículo de análisis • Aug 11
Analyst Estimates: Here's What Brokers Think Of CareRx Corporation (TSE:CRRX) After Its Second-Quarter Report
Last week, you might have seen that CareRx Corporation ( TSE:CRRX ) released its quarterly result to the market. The...Artículo de análisis • Apr 22
Does CareRx (TSE:CRRX) Have A Healthy Balance Sheet?
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to...Artículo de análisis • Mar 17
Market Participants Recognise CareRx Corporation's (TSE:CRRX) Revenues Pushing Shares 28% Higher
CareRx Corporation ( TSE:CRRX ) shares have continued their recent momentum with a 28% gain in the last month alone...Artículo de análisis • Oct 19
CareRx (TSE:CRRX) Takes On Some Risk With Its Use Of Debt
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company...Artículo de análisis • Aug 22
What You Can Learn From CareRx Corporation's (TSE:CRRX) P/S
It's not a stretch to say that CareRx Corporation's ( TSE:CRRX ) price-to-sales (or "P/S") ratio of 0.3x right now...Artículo de análisis • Sep 22
CareRx (TSE:CRRX) Has A Somewhat Strained Balance Sheet
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Artículo de análisis • May 14
These 4 Measures Indicate That CareRx (TSE:CRRX) Is Using Debt Extensively
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Previsiones de crecimiento de beneficios e ingresos
| Fecha | Ingresos | Beneficios | Flujo de caja libre | Flujo de caja operativo | Núm. de analistas medio |
|---|---|---|---|---|---|
| 12/31/2028 | 415 | 8 | 30 | N/A | 3 |
| 12/31/2027 | 406 | 8 | 26 | N/A | 6 |
| 12/31/2026 | 385 | 6 | 16 | 33 | 7 |
| 3/31/2026 | 375 | 27 | 22 | 30 | N/A |
| 12/31/2025 | 370 | 26 | 23 | 31 | N/A |
| 9/30/2025 | 366 | 0 | 21 | 30 | N/A |
| 6/30/2025 | 366 | -2 | 23 | 32 | N/A |
| 3/31/2025 | 367 | -4 | 28 | 36 | N/A |
| 12/31/2024 | 367 | -5 | 30 | 38 | N/A |
| 9/30/2024 | 366 | -6 | 31 | 38 | N/A |
| 6/30/2024 | 367 | -7 | 27 | 34 | N/A |
| 3/31/2024 | 369 | -4 | 23 | 32 | N/A |
| 12/31/2023 | 371 | -5 | 19 | 27 | N/A |
| 9/30/2023 | 374 | -6 | 25 | 33 | N/A |
| 6/30/2023 | 378 | -7 | 30 | 38 | N/A |
| 3/31/2023 | 380 | -34 | 16 | 29 | N/A |
| 12/31/2022 | 382 | -34 | 9 | 22 | N/A |
| 9/30/2022 | 384 | -34 | -4 | 11 | N/A |
| 6/30/2022 | 358 | -36 | -5 | 10 | N/A |
| 3/31/2022 | 311 | -20 | -1 | 8 | N/A |
| 12/31/2021 | 263 | -23 | 0 | 7 | N/A |
| 9/30/2021 | 212 | -21 | 2 | 7 | N/A |
| 6/30/2021 | 187 | -24 | -6 | -3 | N/A |
| 3/31/2021 | 177 | -29 | -2 | 0 | N/A |
| 12/31/2020 | 162 | -18 | -2 | 0 | N/A |
| 9/30/2020 | 148 | -50 | -3 | -1 | N/A |
| 6/30/2020 | 134 | -47 | -2 | 0 | N/A |
| 3/31/2020 | 126 | -34 | -1 | 2 | N/A |
| 12/31/2019 | 125 | -46 | N/A | 6 | N/A |
| 9/30/2019 | 122 | -19 | N/A | 3 | N/A |
| 6/30/2019 | 119 | -20 | N/A | 4 | N/A |
| 3/31/2019 | 117 | -39 | N/A | 9 | N/A |
| 12/31/2018 | 119 | -35 | N/A | 7 | N/A |
| 9/30/2018 | 85 | -27 | N/A | 14 | N/A |
| 6/30/2018 | 97 | -23 | N/A | 12 | N/A |
| 3/31/2018 | 110 | -3 | N/A | 15 | N/A |
| 12/31/2017 | 122 | -4 | N/A | 16 | N/A |
| 9/30/2017 | 168 | -6 | N/A | 14 | N/A |
| 6/30/2017 | 170 | -3 | N/A | 24 | N/A |
| 3/31/2017 | 170 | -13 | N/A | 10 | N/A |
| 12/31/2016 | 167 | -18 | N/A | 2 | N/A |
| 9/30/2016 | 166 | -21 | N/A | 6 | N/A |
| 6/30/2016 | 166 | -34 | N/A | 3 | N/A |
| 3/31/2016 | 164 | -30 | N/A | 20 | N/A |
| 12/31/2015 | 161 | -35 | N/A | 29 | N/A |
| 9/30/2015 | 27 | -47 | N/A | 28 | N/A |
| 6/30/2015 | 60 | -48 | N/A | 22 | N/A |
Previsiones de crecimiento futuro de los analistas
Ingresos vs. Tasa de ahorro: Se prevé que los beneficios de CRRX disminuyan en los próximos 3 años (-54.6% al año).
Beneficios vs. Mercado: Se prevé que los beneficios de CRRX disminuyan en los próximos 3 años (-54.6% al año).
Beneficios de alto crecimiento: Se prevé que los beneficios de CRRX disminuyan en los próximos 3 años.
Ingresos vs. Mercado: Se prevé que los ingresos (4% al año) de CRRX crezcan más despacio que el mercado de Canadian (4.8% al año).
Ingresos de alto crecimiento: Se prevé que los ingresos 4% al año) de CRRX crezcan más despacio que 20% al año.
Previsiones de crecimiento de los beneficios por acción
Rentabilidad financiera futura
ROE futura: Datos insuficientes para determinar si la rentabilidad financiera de CRRX se prevé que sea elevada dentro de 3 años.
Descubre empresas en crecimiento
Análisis de la empresa y estado de los datos financieros
| Datos | Última actualización (huso horario UTC) |
|---|---|
| Análisis de la empresa | 2026/05/31 03:08 |
| Precio de las acciones al final del día | 2026/05/29 00:00 |
| Beneficios | 2026/03/31 |
| Ingresos anuales | 2025/12/31 |
Fuentes de datos
Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.
| Paquete | Datos | Marco temporal | Ejemplo Fuente EE.UU. * |
|---|---|---|---|
| Finanzas de la empresa | 10 años |
| |
| Estimaciones del consenso de analistas | +3 años |
|
|
| Precios de mercado | 30 años |
| |
| Propiedad | 10 años |
| |
| Gestión | 10 años |
| |
| Principales avances | 10 años |
|
* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.
A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.
Modelo de análisis y copo de nieve
Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.
Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.
Métricas industriales y sectoriales
Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.
Fuentes analistas
CareRx Corporation está cubierta por 11 analistas. 7 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.
| Analista | Institución |
|---|---|
| Kyle McPhee | ATB Cormark |
| Kyle McPhee | ATB Cormark Historical (Cormark Securities) |
| Doug Cooper | Beacon Securities Limited |